Burst Biologics recently launched a rebranding of BioBurst Captiv, a new product line that offers cellular therapy solutions for bone regeneration.
Burst Biologics Rebrands Bone Product Line
1 min read Premium comments
Secondary
According to a press release, Captiv allografts can support bone regeneration in spinal fusions and general orthopedic surgeries. BioBurst Captiv come in sponges, strips, granules and putty.
“After solidifying brands for its two fluid allograft product lines, BioBurst Fluid and BioBurst Rejuv, Burst Biologics turned to its popular line of bone products for a long-awaited refresh. This rebranding effort culminated in BioBurst Captiv, a name that evokes the ‘captivating’ results patients and physicians have seen from these products,” the press release states.
In addition, the new look is meant to represent “the way Captiv bone products stand out in the bone consolidation space.”
Burst Biologics CEO Chris Jones said in the release, “As a result of feedback we received, the company has placed its efforts into rebranding our bone product line to reflect just how special it is.”
He added, “Physicians have been using our bone products for several years now to help patients recover from difficult surgeries. We are proud to provide such a dynamic portfolio of products.”
Burst Biologics is a medical research and biotechnology company headquartered in Boise, Idaho. Learn more about the company and their line of products at http://www.BurstBiologics.com/products.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.